Squarepoint
ACET icon

Squarepoint’s Adicet Bio ACET Stock Holding History

Squarepoint’s Portfolio ACET Stock Details ACET Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-55,723
Closed -$469K – 4193
2025
Q4 		$469K Buy
55,723
+52,821
+1,820% +$584K ﹤0.01% 3268
2025
Q3 		$37.6K Buy
+2,902
New +$34.2K ﹤0.01% 4250
2025
Q2 		– Sell
-723
Closed -$8.73K – 4429
2025
Q1 		$8.73K Sell
723
-10,799
-94% -$154K ﹤0.01% 4461
2024
Q4 		$177K Buy
+11,522
New +$217K ﹤0.01% 4513
2024
Q3 		– Sell
-22,639
Closed -$438K – 4046
2024
Q2 		$438K Buy
22,639
+21,839
+2,730% +$585K ﹤0.01% 3179
2024
Q1 		$30.1K Sell
800
-965
-55% -$39.9K ﹤0.01% 3903
2023
Q4 		$53.4K Buy
1,765
+114
+7% +$2.49K ﹤0.01% 3841
2023
Q3 		$36.2K Buy
1,651
+941
+133% +$33.2K ﹤0.01% 3663
2023
Q2 		$27.6K Sell
710
-264
-27% -$23.3K ﹤0.01% 3477
2023
Q1 		$89.8K Sell
974
-40
-4% -$5.02K ﹤0.01% 2987
2022
Q4 		$145K Buy
+1,014
New +$253K ﹤0.01% 2882
2020
Q3 		– Sell
-545
Closed -$131K – 2442
2020
Q2 		$131K Buy
+545
New +$107K ﹤0.01% 1951

Other funds holding ACET

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

Squarepoint's ACET Position: Q1 2026 in Review

Squarepoint sold out of Adicet Bio (ACET) in Q1 2026, closing a stake of 55,723 shares — an estimated $469K sold.

Squarepoint first reported a position in ACET in Q2 2020 and held it in 12 quarters. The position peaked at $469K in Q4 2025. 49 funds tracked by Wall St. Rank hold ACET as of Q1 2026.

  • Squarepoint reported no remaining Adicet Bio position as of Q1 2026 after selling out during the quarter.
  • Squarepoint sold 55,723 Adicet Bio shares in Q1 2026, an estimated $469K.
  • Squarepoint first reported a position in Adicet Bio in Q2 2020 and held it in 12 quarters.
  • Squarepoint's Adicet Bio position peaked at $469K in Q4 2025.
  • 49 funds tracked by Wall St. Rank held Adicet Bio as of Q1 2026.

Based on Squarepoint's 13F filing for Q1 2026, filed 15 May 2026.